729 related articles for article (PubMed ID: 28848099)
21. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
[TBL] [Abstract][Full Text] [Related]
23. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
[TBL] [Abstract][Full Text] [Related]
24. Cognitive performance correlates with the degree of dopaminergic degeneration in the associative part of the striatum in non-demented Parkinson's patients.
Kübler D; Schroll H; Buchert R; Kühn AA
J Neural Transm (Vienna); 2017 Sep; 124(9):1073-1081. PubMed ID: 28643101
[TBL] [Abstract][Full Text] [Related]
25. Gray matter correlates of dopaminergic degeneration in Parkinson's disease: A hybrid PET/MR study using (18) F-FP-CIT.
Choi H; Cheon GJ; Kim HJ; Choi SH; Kim YI; Kang KW; Chung JK; Kim EE; Lee DS
Hum Brain Mapp; 2016 May; 37(5):1710-21. PubMed ID: 26846350
[TBL] [Abstract][Full Text] [Related]
26. Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease.
Lokkegaard A; Werdelin LM; Regeur L; Karlsborg M; Jensen SR; Brødsgaard E; Madsen FF; Lonsdale MN; Friberg L
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):508-16. PubMed ID: 17096096
[TBL] [Abstract][Full Text] [Related]
27. Correlations between dopamine transporter density measured by
Maekawa T; Sato N; Ota M; Sugiyama A; Sone D; Enokizono M; Kimura Y; Mukai Y; Murata M; Takano H; Imabayashi E; Matsuda H; Kunimatsu A; Abe O
Jpn J Radiol; 2017 Dec; 35(12):755-759. PubMed ID: 29063467
[TBL] [Abstract][Full Text] [Related]
28. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a
Pilotto A; Schiano di Cola F; Premi E; Grasso R; Turrone R; Gipponi S; Scalvini A; Cottini E; Paghera B; Garibotto V; Rizzetti MC; Bonanni L; Borroni B; Morbelli S; Nobili F; Guerra UP; Perani D; Padovani A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1642-1651. PubMed ID: 31098748
[TBL] [Abstract][Full Text] [Related]
29. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
[TBL] [Abstract][Full Text] [Related]
30. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.
Colloby SJ; Williams ED; Burn DJ; Lloyd JJ; McKeith IG; O'Brien JT
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1176-85. PubMed ID: 15931516
[TBL] [Abstract][Full Text] [Related]
31. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.
Spiegel J; Hellwig D; Möllers MO; Behnke S; Jost W; Fassbender K; Samnick S; Dillmann U; Becker G; Kirsch CM
Brain; 2006 May; 129(Pt 5):1188-93. PubMed ID: 16513685
[TBL] [Abstract][Full Text] [Related]
32. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
33. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.
Pirker W; Djamshidian S; Asenbaum S; Gerschlager W; Tribl G; Hoffmann M; Brücke T
Mov Disord; 2002 Jan; 17(1):45-53. PubMed ID: 11835438
[TBL] [Abstract][Full Text] [Related]
34. [Striatal dopamine transporter levels in patients with REM sleep behavior disorder: assessment with 123I-FP-CIT SPECT].
Mossa EP; Niccoli Asabella A; Iuele F; Stabile Ianora AA; Giganti M; Rubini G
Recenti Prog Med; 2012 Nov; 103(11):500-4. PubMed ID: 23096739
[TBL] [Abstract][Full Text] [Related]
35. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
36. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
[TBL] [Abstract][Full Text] [Related]
37. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease.
Covelli EM; Brunetti A; Di Lauro A; Sullo P; Mazzarella G; Tedeschi E; Belfiore G
Radiol Med; 2004 Oct; 108(4):417-25. PubMed ID: 15525895
[TBL] [Abstract][Full Text] [Related]
39. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.
Eshuis SA; Jager PL; Maguire RP; Jonkman S; Dierckx RA; Leenders KL
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):454-62. PubMed ID: 19037637
[TBL] [Abstract][Full Text] [Related]
40. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
